JMP reiterates Sangamo at market outperform

Sangamo Biosciences, Inc. was reiterated by JMP Securities analyst Charles C. Duncan at a market outperform rating and an $8 price target after the company announced its 2006 value-adding objectives. Clinical data for the company's proprietary zinc-finger technology for the treatment of HIV is expected this year. Shares of the Richmond, Calif., biopharmaceutical company were up 41 cents, or 8.93%, at $5.00 on volume of 985,900 shares versus the three-month running average of 77,787 shares. (Nasdaq: SGMO)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.